| 29.49 0.55 (1.9%) | 02-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.42  |
1-year : | 39.94 |
| Resists | First : | 31.18 |
Second : | 34.2 |
| Pivot price | 28.84 |
|||
| Supports | First : | 26.3 |
Second : | 21.88 |
| MAs | MA(5) : | 28.66  |
MA(20) : | 29.73 |
| MA(100) : | 28.86 |
MA(250) : | 21.04 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 46.4 |
D(3) : | 30.2 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 34.29 | Low : | 9.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VRDN ] has closed below upper band by 29.6%. Bollinger Bands are 33.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.58 - 29.72 | 29.72 - 29.85 |
| Low: | 25.98 - 26.13 | 26.13 - 26.27 |
| Close: | 29.22 - 29.48 | 29.48 - 29.72 |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Fri, 27 Feb 2026
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
Fri, 27 Feb 2026
Jefferies Maintains Buy, PT $45 for Viridian Therapeutics (VRDN) Feb 2026 - Meyka
Thu, 26 Feb 2026
Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Misses Expectations By $0.18 EPS - MarketBeat
Thu, 26 Feb 2026
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 26 Feb 2026
Viridian Therapeutics Reports Q4 and Full Year 2025 Financial Results - TradingView
Thu, 26 Feb 2026
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 9.541e+007 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 8,680 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.2416e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -56.8 % |
| Return on Assets (ttm) | -30.1 % |
| Return on Equity (ttm) | -49.9 % |
| Qtrly Rev. Growth | 81 % |
| Gross Profit (p.s.) | 977.65 |
| Sales Per Share | 7.22347e+007 |
| EBITDA (p.s.) | -2.52439e+008 |
| Qtrly Earnings Growth | -3.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -326 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 7.56 |
| Dividend | 0 |
| Forward Dividend | 7.94e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|